Rhumbline Advisers Has $3.77 Million Stock Holdings in Twist Bioscience Corporation $TWST

Rhumbline Advisers lifted its position in Twist Bioscience Corporation (NASDAQ:TWST) by 5.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 95,964 shares of the company’s stock after acquiring an additional 4,571 shares during the period. Rhumbline Advisers owned approximately 0.16% of Twist Bioscience worth $3,768,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of TWST. Cetera Investment Advisers acquired a new stake in Twist Bioscience during the 4th quarter worth approximately $220,000. Deutsche Bank AG raised its holdings in Twist Bioscience by 8.8% during the 4th quarter. Deutsche Bank AG now owns 159,752 shares of the company’s stock worth $7,424,000 after buying an additional 12,940 shares during the period. D. E. Shaw & Co. Inc. raised its holdings in Twist Bioscience by 1,085.9% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 107,268 shares of the company’s stock worth $4,985,000 after buying an additional 98,223 shares during the period. Lazard Asset Management LLC raised its holdings in Twist Bioscience by 39.0% during the 4th quarter. Lazard Asset Management LLC now owns 27,881 shares of the company’s stock worth $1,295,000 after buying an additional 7,827 shares during the period. Finally, Nuveen Asset Management LLC raised its holdings in Twist Bioscience by 43.8% during the 4th quarter. Nuveen Asset Management LLC now owns 292,645 shares of the company’s stock worth $13,599,000 after buying an additional 89,170 shares during the period.

Twist Bioscience Trading Down 1.2%

TWST stock opened at $25.31 on Monday. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.90 and a quick ratio of 3.60. The company has a fifty day moving average price of $30.52 and a two-hundred day moving average price of $34.18. Twist Bioscience Corporation has a one year low of $24.07 and a one year high of $55.33. The stock has a market cap of $1.53 billion, a price-to-earnings ratio of -17.46 and a beta of 2.31.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Monday, August 4th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.07. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%.The company had revenue of $96.06 million during the quarter, compared to the consensus estimate of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Equities analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Insider Transactions at Twist Bioscience

In related news, CFO Adam Laponis sold 2,449 shares of the company’s stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $38.15, for a total transaction of $93,429.35. Following the completion of the sale, the chief financial officer owned 103,569 shares of the company’s stock, valued at $3,951,157.35. This represents a 2.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Emily M. Leproust sold 2,265 shares of the firm’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $25.76, for a total transaction of $58,346.40. Following the completion of the transaction, the chief executive officer directly owned 634,740 shares in the company, valued at approximately $16,350,902.40. This represents a 0.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 8,911 shares of company stock valued at $288,159. 3.01% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have commented on TWST. Evercore ISI set a $46.00 target price on shares of Twist Bioscience in a report on Monday, August 4th. Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a research note on Monday, August 4th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $49.40.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.